{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:30:53Z","timestamp":1775129453839,"version":"3.50.1"},"reference-count":23,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Recently several patients, who developed Guillain\u2013Barr\u00e9 syndrome characterized by prominent bifacial weakness after ChAdOx1 nCoV-19 vaccination, were described from different centers. We recently observed a patient who developed a similar syndrome, later in the follow up he showed worsening of the neuropathy two months after the initial presentation. Repeat EMG showed reduced nerve sensory and motor conduction velocities of both upper and lower limbs, and a diagnosis of chronic inflammatory demyelinating polyneuropathy (typical CIDP) was made according to established criteria. Our report expands on the possible outcomes in patients who develop Guillain\u2013Barr\u00e8 syndrome after COVID-19 vaccinations and suggest that close monitoring after the acute phase is needed in these patients to exclude a chronic evolution of the disease, which has important implications for long-term treatment.<\/jats:p>","DOI":"10.3390\/vaccines9121502","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:40:32Z","timestamp":1639968032000},"page":"1502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination"],"prefix":"10.3390","volume":"9","author":[{"given":"Caterina Francesca","family":"Bagella","sequence":"first","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide G.","family":"Corda","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Zara","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Emanuele","family":"Elia","sequence":"additional","affiliation":[{"name":"Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Ruiu","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Solla","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria Sassari, Unit of Neurology, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/brain\/awaa444","article-title":"COVID-19 vaccine and Guillain-Barr\u00e9 syndrome: Let\u2019s not leap to associations","volume":"144","author":"Lunn","year":"2021","journal-title":"Brain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","article-title":"Vaccine-preventable diseases, vaccines and Guillain-Barre\u2019 syndrome","volume":"37","author":"Principi","year":"2019","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000339248","article-title":"Vaccine Safety Datalink Research Team. Guillain-Barr\u00e9 syndrome incidence in a large United States cohort (2000\u20132009)","volume":"39","author":"Shui","year":"2012","journal-title":"Neuroepidemiology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"GBS Classification Group; GBS Classification Group. Guillain-Barr\u00e9 and Miller Fisher syndromes--new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 Syndrome Variant Occurring after SARS-CoV-2 Vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 Vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bonifacio, G.B., Patel, D., Cook, S., Purcaru, E., Couzins, M., Domjan, J., Ryan, S., Alareed, A., Tuohy, O., and Slaght, S. (2021). Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine. J. Neurol. Neurosurg. Psychiatry, Online ahead of print.","DOI":"10.1136\/jnnp-2021-327027"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e244125","DOI":"10.1136\/bcr-2021-244125","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1007\/s10072-021-05467-w","article-title":"A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine","volume":"17","author":"Nasuelli","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Van den Bergh, P.Y.K., van Doorn, P.A., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Allen, J.A., Attarian, S., Blomkwist-Markens, P.H., Cornblath, D.R., and Eftimov, F. (2021). European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. Eur. J. Neurol.","DOI":"10.1111\/ene.14959"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pegat, A., Vogrig, A., Khouri, C., Masmoudi, K., Vial, T., and Bernard, E. (2021). Adenovirus COVID-19 vaccines and Guillain-Barr\u00e9 syndrome with facial paralysis. Ann. Neurol.","DOI":"10.1002\/ana.26258"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"577719","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 vaccine and Guillain- Barr\u00e9 Syndrome in Tasmania: A causal link?","volume":"360","author":"Oo","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1002\/mus.26477","article-title":"Bell\u2019s palsy and guillain-barr\u00e9 syndrome may be 2 ends of the same spectrum","volume":"59","author":"Mathew","year":"2019","journal-title":"Muscle Nerve."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/WCO.0000000000000725","article-title":"Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"32","author":"Querol","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ene.14044","article-title":"Italian CIDP Database Study Group. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database","volume":"27","author":"Doneddu","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CND.0b013e318285256b","article-title":"Distal acquired demyelinating symmetric neuropathy after vaccination","volume":"14","author":"Gable","year":"2013","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jocn.2020.05.016","article-title":"Facial diplegia, a possible atypical variant of Guillain-Barr\u00e9 Syndrome as a rare neurological complication of SARS-CoV-2","volume":"77","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1111\/ene.14860","article-title":"Prevalence, clinical characteristics and outcomes of Guillain-Barr\u00e9 syndrome spectrum associated with COVID-19: A systematic review and meta-analysis","volume":"28","author":"Palaiodimou","year":"2021","journal-title":"Eur. J. Neurol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:51:57Z","timestamp":1760169117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,19]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["vaccines9121502"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9121502","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,19]]}}}